Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clinical Trials

Set Alert for Clinical Trials

After US Approval, BeiGene Set To Gain Sixth PD-1 Green Light In China

Beijing-based BeiGene is set to score two big wins in a row as it pursues innovation. After securing US approval for its BTK inhibitor zanubrutinib for mantle cell lymphoma, its PD-1 inhibitor has sailed through a technical review in China.
China Research & Development

ResTORbio Pins Hopes On Parkinson’s After Failed CSRI Study

Company terminates studies of its TORC1 blocker after it fails to prevent respiratory illness in elderly patients with clinically symptomatic respiratory illness (CSRI). ResTORbio is hoping the same drug will be effective in Parkinson’s disease.
Clinical Trials Research & Development

NASH Companies Take The Stage At AASLD

NGM’s injectable might be best-suited as induction therapy for sicker NASH patients, Inventiva hopes its pan-PPAR agonist will outperform Genfit’s elafibranor, and Albireo thinks IBAT inhibition offers promise in NASH.

Research and Development Strategies Clinical Trials

BioMarin’s Momentum Grows With Twin Blockbuster Plans

The frontrunner in hemophilia A gene therapy has been hit by data doubts, but this and achondroplasia drug could deliver in 2020.

Clinical Trials FDA

No Alarm At Almirall Despite Stake Sale

Shares in the Spanish dermatology specialist have slipped as the majority shareholder sold a 6.3% stake. However, sales of its psoriasis and acne drugs, plus some promising late-stage assets, suggest Almirall is in rude health.

Sales & Earnings Dermatology

HES Flare: GSK's Nucala Edges Forward

GlaxoSmithKline’s interleukin-5 inhibitor, Nucala (mepolizumab), is the first treatment shown to reduce the hypereosinophilic syndrome flare-ups in a 100-patient pivotal study.

 

 

 

Immune Disorders Clinical Trials

J&J Targets Tremfya Growth In PsA

The healthcare giant is looking for a second approval for its IL-23 blocker and tells Scrip the results from the DISCOVER program show that the drug can make its mark in psoriatic arthritis as well as psoriasis.
Immune Disorders Clinical Trials

Adverse Event Concerns With Solid Biosciences' Candidate DMD Gene Therapy

The US FDA has for the second time placed a clinical hold on Solid Biosciences’ potential gene therapy for Duchenne muscular dystrophy, a move linked to a 70% decline in the company’s share price. The company had reported a serious adverse event in a patient treated with higher doses of the viral vector-delivered gene therapy.

 

Gene Therapy Clinical Trials

Japan Cancer Center Looks To Leverage Expertise As It Builds Pharma Ties

Japan's largest cancer center is looking to build on its tissue sample and genomic resources to further build its reputation as a partner facility for the pharma industry's oncology trials. 
Japan Cancer
See All
UsernamePublicRestriction

Register